


- > In Q1 2016, **£350m (£129m)** was invested in **34 (38)** deals of over £0.5m by **66** investors
- > The busiest investors were Imperial Innovations, Woodford Investment Management, Cambridge Innovation, Medicxi, NeoMed, New Science Ventures, Oxford Capital and Sofinnova
- > **51%** of deals were less than **£5m** in value, these received **11%** of money invested
- > Private investors participated in **35%** (38%) of deals and Crowdfunding platforms financed **6%** (0%) of deals
- > Corporate investors participated in **21%** of deals, European investors in **15%** and US Investors in **18%**
- > There have been four primary areas of investment focus – Therapeutics (**£125m, 9 companies**), Devices/Diagnostics (**£70m, 10 companies**), Biotech/Clinical Services (**£117m, 8 companies**) and Health Software/Online Services (**£29m, 5 companies**). In addition, **2** companies who could not be simply categorised, together just under **£10m**.



- > The 10 biggest deals (with disclosed values) received **72%** of funds invested, were:

Mission Therapeutics	£60m
Autolus	£40m
Inivata	£31m
Iterum Therapeutics	£28m
4Tech	£20m
Babylon Health	£17m
Atlantic Healthcare	£17m
Cambridge Epigenetix	£15m
Precision Ocular	£14m
Capella BioScience	£11m

- > The most active regions were Ireland, London and Cambridge which were responsible for **29%**, **26%** and **24%** of deals respectively.
- > The Cambridge, London and Ireland received **39%**, **28%** and **23%** (respectively) of the funds invested in the UK and Ireland. All other regions took less than **5%**.
- > On a City basis: Cambridge, London and Dublin had multiple LS transactions and together were responsible for **61%** of deals, all other cities only had a single deal in this quarter

